Formic Acid

Formic Acid

SCHEMBL7223577

Cn1nnc([C@H]2O[C@@H](n3cnc4c(NC5CCCC5)nc(N(CO)CCc5ccccc5)nc43)[C@H](O)[C@@H]2O)n1.O=CO

nearest known ligand 0.49

Full drug profile on Sugi Atlas →

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 7/20 0.49
ADORA2A P29274 6/20 0.49
ADORA1 P30542 6/20 0.49
ADORA2B P29275 4/20 0.49
NT5E P21589 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7459232 0.97 ADORA3 (0.52) ADORA3ADORA2AADORA1ADORA2B
Formic Acid SCHEMBL7229560 0.92 ADORA3 (0.60) ADORA3ADORA2AADORA1ADORA2B
SCHEMBL7223581 0.91 ADORA3 (0.46) ADORA3ADORA2AADORA1ADORA2BNT5E
SCHEMBL5086124 0.89 ADORA3 (0.63) ADORA3ADORA2AADORA1ADORA2B
Formic Acid SCHEMBL7221846 0.87 ADORA3 (0.44) ADORA3ADORA2AADORA1ADORA2B
Formic Acid SCHEMBL7231158 0.87 ADORA2A (0.48) ADORA3ADORA2AADORA1ADORA2B
Formic Acid SCHEMBL7230913 0.87 ADORA3 (0.54) ADORA3ADORA2AADORA1ADORA2B
Formic Acid SCHEMBL7232089 0.85 ADORA3 (0.55) ADORA3ADORA2AADORA1ADORA2B
SCHEMBL7229569 0.84 ADORA3 (0.52) ADORA3ADORA2AADORA1ADORA2B
SCHEMBL7455168 0.83 ADORA3 (0.47) ADORA3ADORA2AADORA1ADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6528494-B2 Antiinflammatory agents COX BRIAN (GB) 2003-03-04 US disclosed
EP-0948509-B1 2-(PURIN-9-YL)-TETRAHYDROFURAN-3,4-DIOL DERIVATIVES GLAXO GROUP LTD (GB) 2002-10-16 EP disclosed
US-6426337-B1 ANTIINFLAMMATORY AGENTS SMITHKLINE BEECHAM CORPORATION 2002-07-30 US disclosed